Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization time 18% Improvement Relative Risk HCQ for COVID-19  Alqassieh et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Prospective study of 131 patients in Jordan Shorter hospitalization with HCQ (not stat. sig., p=0.11) c19hcq.org Alqassieh et al., F1000Research, Prepr.., Dec 2020 Favors HCQ Favors control

Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan

Alqassieh et al., F1000Research, Preprint
Dec 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Prospective observational study of 131 COVID-19 patients in Jordan, showing 18% shorter hospital stay with HCQ, p = 0.11.
hospitalization time, 18.2% lower, relative time 0.82, p = 0.11, treatment 63, control 68.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alqassieh et al., 10 Dec 2020, prospective, Jordan, preprint, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan
Rami S Alqassieh, Isam K Bsisu, Mohammed Qussay Al-Sabbagh, Naser M El-Hammuri, Moh’d A Yousef, Mohammad A El Jarbeh, Ahmed A Sharqawi, Heba Z Smadi, Sami A Abu-Halaweh, Mohammad M Abufaraj
F1000Research, doi:10.12688/f1000research.27419.1
Background: On March 11th, 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a global pandemic. Healthcare systems in low-and middle-income countries may face serious limitations during a pandemic, for which understanding the predictors of prolonged hospital stay are crucial in decreasing the mortality rate. The aim of this study was to investigate the predictors of increased length of hospitalization among COVID-19 patients. Methods: In this prospective study, we investigated the effect of presenting symptoms and laboratory investigations on the duration of hospitalization of 131 COVID-19 patients at a tertiary hospital in Jordan from March 17th to April 9th, 2020. Results: Patients median age was 24 years [interquartile range (IQR): 8-39], of which 67 (51.15%) were males and 64 (48.85%) were females. Smokers had shorter in-hospital stay (OR: -3.52; 95% CI: -6.73 to -0.32; P=0.03). Taste loss (OR: 5.1; 95% CI: 1.95 to 8.25; P<0.01) and chills or rigors (OR: 4.08; 95% CI: 0.73 to 7.43; P=0.02) were the symptoms significantly associated with increased in-hospital stay, while those who had malaise (OR: -4.98; 95% CI: -8.42 to -1.59; P<0.01) and high white blood cell (WBC) count (OR: -0.74; 95% CI: -1.31 to -0.17; P=0.01) had faster recovery. Conclusions: Our study found that the most common presenting Open Peer Review Reviewer Status
References
Bsisu, Alqassieh, Abu-Halaweh, Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan, doi:10.7910/DVN/SBV1K6
Chen, Wu, Guo, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, doi:10.1172/JCI137244
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, doi:10.1016/S0140-6736(20)30211-7
Cucinotta, Vanelli, WHO Declares COVID-19 a Pandemic, Acta Biomed, doi:10.23750/abm.v91i1.9397
De Jager, Wever, Gemen, The neutrophil-lymphocyte count ratio in patients with community-acquired pneumonia, Lancet Respir Med, doi:10.1016/S2213-2600(20)30239-3
Dreher, Kersten, Bickenbach, The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS, Dtsch Arztebl Int, doi:10.3238/arztebl.2020.0271
El-Aziz, Stockand, Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) -an update on the status, Infect Genet Evol, doi:10.1016/j.meegid.2020.104327
Farsalinos, Niaura, Houezec, Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system, Toxicol Rep, doi:10.1016/j.toxrep.2020.04.012
Fatima, Asif, Khan, Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease, Ann Med Surg (Lond), doi:10.1016/j.amsu.2020.11.027
Hopman, Allegranzi, Mehtar, Managing COVID-19 in Low-and Middle-Income Countries, JAMA, doi:10.1001/jama.2020.4169
Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med, doi:10.1056/NEJMoa2021436
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Ji, Ma, Peppelenbosch, Potential association between COVID-19 mortality and health-care resource availability, Lancet Glob Health, doi:10.1016/S2214-109X(20)30068-1
Lai, Shih, Ko, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105924
Li, Guan, Wu, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, N Engl J Med, doi:10.1056/NEJMoa2001316
Mcmichael, Currie, Clark, Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington, N Engl J Med, doi:10.1056/NEJMoa2005412
Mehra, Desai, Ruschitzka, RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, The Lancet, doi:10.1016/S0140-6736(20)31180-6
Munster, Koopmans, Van Doremalen, A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment, N Engl J Med, doi:10.1056/NEJMp2000929
Peeri, Shrestha, Rahman, The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?, Int J Epidemiol, doi:10.1093/ije/dyaa033
Rio, Malani, Translating Science on COVID-19 to Improve Clinical Care and Support the Public Health Response, JAMA, doi:10.1001/jama.2020.9252
Rome, Avorn, Drug Evaluation during the Covid-19 Pandemic, N Engl J Med, doi:10.1056/NEJMp2009457
Sheridan, Fast, portable tests come online to curb coronavirus pandemic, Nat Biotechnol, doi:10.1038/d41587-020-00010-2
Siow, Liew, Shrestha, Managing COVID-19 in resource-limited settings: critical care considerations, Crit Care, doi:10.1186/s13054-020-02890-x
Spinato, Fabbris, Polesel, Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection, JAMA, doi:10.1001/jama.2020.6771
Suleiman, Bsisu, Guzu, Preparedness of Frontline Doctors in Jordan Healthcare Facilities to COVID-19 Outbreak, Int J Environ Res Public Health, doi:10.3390/ijerph17093181
Vaira, Salzano, Deiana, Anosmia and Ageusia: Common Findings in COVID-19 Patients, Laryngoscope, doi:10.1002/lary.28692
Weiss, Navas-Martin, Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus, Microbiol Mol Biol Rev
Yusef, Hayajneh, Awad, Large Outbreak of Coronavirus Disease among Wedding Attendees, Jordan, Emerg Infect Dis, doi:10.3201/eid2609.201469
Zhang, Yan, Fan, D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19, J Thromb Haemost
Zheng, Ma, Zhang, COVID-19 and the cardiovascular system, Nat Rev Cardiol, doi:10.1038/s41569-020-0360-5
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zhu, Zhang, Wang, A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit